Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

modified PENTOCLO (mPENTOCLO)

Phase 3Small molecule

SSunnybrook Health Sciences Centre

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoradionecrosisRecruiting

OsteoradionecrosisPhase 3

Recruiting

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Osteoradionecrosis

NCT06055257

Clinical

Trials by Indication[1]

Osteoradionecrosis1 trial

Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible

Recruiting·SSunnybrook Health Sciences Centre·Phase 3·NCT06055257·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for modified PENTOCLO (mPENTOCLO). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — modified PENTOCLO (mPENTOCLO) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for modified PENTOCLO (mPENTOCLO). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sunnybrook Health Sciences Centre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSunnybrook Health Sciences Centre

Related News